- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GSK Makes Post-Brexit Investment in UK
July 27, 2016
GSK has announced £275 million ($360m) of new investments at three of its manufacturing sites in the UK. The news comes as a business confidence booster for the country following its Brexit vote last month.
The new investment will be made across three UK sites:
Barnard Castle in County Durham, one of GSK’s biggest secondary manufacturing sites, employing 1,100 people.
Montrose in Angus, Scotland, which manufactures active ingredients for respiratory, HIV and vaccine products and employs over 450 staff.
Ware (Hertfordshire), which employs 1200 staff manufacturing innovative respiratory products.
GSK chief Andrew Witty said: "It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here."
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
